This HTML5 document contains 141 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1530/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q35665113
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel article scientifique artikull shkencor artículo científico publicado en 2012 naučni članak scientific article published on 9 January 2012 2012年论文 2012 nî lūn-bûn научная статья artykuł naukowy artigo científico 2012年論文 articol științific teaduslik artikkel 2012年论文 artículu científicu espublizáu en 2012 գիտական հոդված научни чланак 2012年論文 vetenskaplig artikel vedecký článok article científic article scientific 2012年论文 artigo científico scientific article published on 9 January 2012 επιστημονικό άρθρο научна статия videnskabelig artikel مقالة علمية نشرت في 9 يناير 2012 мақолаи илмӣ 2012年論文 ৯ জানুয়ারি ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ מאמר מדעי 2012年论文 vitenskapelig artikkel artikel ilmiah artikulong pang-agham tieteellinen artikkeli บทความทางวิทยาศาสตร์ наукова стаття, опублікована в січні 2012 bài báo khoa học 2012年の論文 სამეცნიერო სტატია scienca artikolo wissenschaftlicher Artikel mokslinis straipsnis 2012年论文 научни чланак artigo científico tudományos cikk scientific article published on 9 January 2012 2012年論文 мақолаи илмӣ articolo scientifico 2012年论文 2012년 논문 vědecký článek bilimsel makale 2012年論文 vitskapeleg artikkel
p:P577
wds:Q35665113-F3C0F634-8F94-4BE9-90E1-8CE2047A9E06
wdt:P577
2012-01-09T00:00:00Z
p:P2860
wds:Q35665113-C85A3226-207F-4E55-837E-E9C36712E0B3 wds:Q35665113-AFD47D15-4EDB-4979-BAE2-D5697C49A0C9 wds:Q35665113-BAA2C4B9-008E-4734-ACE4-5EB91DBF51E5 wds:Q35665113-68FD7E61-79CC-4CD7-ACB6-6D6E1561A5B7 wds:Q35665113-7B9B697D-D211-4337-B702-71213B346CA2 wds:Q35665113-3DD01299-F27B-4907-8AF0-647750557ADC wds:Q35665113-42C1850B-0EB8-4F1B-8083-3B0760791A05 wds:Q35665113-20377234-14C6-4772-B20D-CEB14600BACD wds:Q35665113-34183C50-7969-43F1-93F2-F7F06A51780E wds:Q35665113-14952061-A179-4C90-B904-17C934E8509B wds:Q35665113-16CA5195-9141-47B2-9046-71D1BB3D13A5
wdt:P2860
wd:Q46900223 wd:Q33347264 wd:Q81242198 wd:Q34743520 wd:Q36335402 wd:Q37182173 wd:Q33375270 wd:Q28263732 wd:Q83761732 wd:Q46716129 wd:Q28131668
p:P2093
wds:Q35665113-823612D9-C4ED-4452-8D3E-E4AAEDEB4C07 wds:Q35665113-EA7244DE-4C93-48CD-B4C6-83B3CD707944 wds:Q35665113-DF897AC7-CC1D-4A55-8B9A-029C85A8E84F wds:Q35665113-31F39A1C-058A-4699-8153-D14122328073 wds:Q35665113-555AD628-D89B-404B-9974-8189DBC10028 wds:Q35665113-0AA20274-BA8D-41EC-8BD1-FAFBECB1F3F9 wds:Q35665113-139739D4-F938-4B41-91BF-8A99888DB291 wds:Q35665113-D29B65BE-DDAB-4F3E-A805-FBE29B1B7271 wds:Q35665113-6B8A07C8-7123-498E-A8AF-0A04C4F56EC6 wds:Q35665113-63E626D7-DEBC-4BB9-B300-272495592C19
wdt:P2093
Anastasios Ntavatzikos Nikolaos Economopoulos George Kanakis Stavroula Antoniou George Dimitriadis Anna Koumarianou Nikolaos Tsavaris Dimitra Rontogianni Dimitrios Pectasides Gregory Kaltsas
rdfs:label
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
skos:prefLabel
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
schema:name
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
p:P50
wds:Q35665113-ABAEC6AC-8163-49E0-BC04-35075012722E
wdt:P50
wd:Q83327227
p:P1476
wds:Q35665113-AA8EF358-BBA6-42A8-8253-BDA26B222E45
wdt:P1476
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
p:P304
wds:Q35665113-9A8F2AEF-A54A-4190-B9C3-C8EDB24D5CD6
wdt:P304
L1-4
p:P31
wds:Q35665113-0D0264DA-C9EA-49C7-B918-C462ABE88218
wdt:P31
wd:Q13442814
p:P921
wds:Q35665113-D934D0B2-E6CC-4ECB-BF20-1E03C0699DE5 wds:Q35665113-B86C959B-247A-49F9-A380-9DDEABF60C73
wdt:P921
wd:Q425088 wd:Q413299
p:P698
wds:Q35665113-CCF9A2D7-3374-4197-B2EA-AFA803B4A48C
wdtn:P698
n12:22232542
wdt:P698
22232542
p:P1433
wds:Q35665113-081AC471-1848-4099-B270-41831C8B11D0
wdt:P1433
wd:Q3054004
p:P433
wds:Q35665113-A4F275FD-8A9F-4EC1-9224-D2060CCFCFE2
p:P478
wds:Q35665113-1F35BC70-2365-4B8B-B990-F7762EC0EE23
wdt:P433
1
wdt:P478
19
p:P356
wds:Q35665113-5661957B-CBB3-45EF-81BA-9CDCE2635F7D
wdtn:P356
n10:ERC-11-0287
wdt:P356
10.1530/ERC-11-0287
p:P932
wds:Q35665113-BB24EF3A-0C52-41E8-9E8D-4E58EBAD5FE7
wdt:P932
3255566